Shanghai Yizhong Pharmaceutical News

Shanghai Yizhong (688091) Company Incident Review Report: Guidelines to Strengthen the Influence of Paclitaxel Micelles and Steady Revenue Growth

華鑫證券Aug 18, 2023 16:13

Shanghai Yizhong (688091): Paclitaxel micellar included in Shanghai's “New Excellent Pharmaceutical” catalogue

國金證券May 12, 2023 00:00

Shanghai Yizhong (688091) Company Comment: Paclitaxel polymer micelles are recommended by CSCO Clinical Guidelines Level 1

國金證券Apr 25, 2023 07:23

Shanghai Yizhong (688091) Company Comment: Paclitaxel micellar sales in a single season, production capacity of nearly 100 million dollars can be expected to accumulate momentum

國金證券Apr 25, 2023 00:00

Shanghai Yizhong (688091) Company In-depth Report: Focus on the cancer field and firmly innovate independently

華鑫證券Apr 10, 2023 00:00

Shanghai Yizhong (688091) Company Comment: Paclitaxel micellar emissions are increasing and admission to hospitals is about to accelerate

國金證券Mar 31, 2023 00:00

Shanghai Yizhong (688091): Paclitaxel micellar sales were 236 million, up 5687% year-on-year

國金證券Mar 1, 2023 16:17